s, the
ability of the Company to make its ERCC-1 molecular diagnostic test
available in the first quarter of 2008, or at all, and other statements
identified by words such as "projects," "may," "could," "would," "should,"
"believes," "expects," "anticipates," "estimates," "intends," "plans" or
similar expressions.
These statements are based upon the current beliefs and expectations of
the Company's management and are subject to significant risks and
uncertainties, including those detailed in the Company's filings with the
Securities and Exchange Commission. Actual results, including, without
limitation, actual sales results, if any, or the application of funds, may
differ from those set forth in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties that are
subject to change based on various factors (many of which are beyond the
Company's control). The Company undertakes no obligation to publicly update
forward-looking statements, whether because of new information, future
events or otherwise, except as required by law.
RESPONSE GENETICS, INC.
CONSOLIDATED BALANCE SHEETS
As of As of
December 31, September 30,
2006 2007
(Unaudited)
ASSETS
Current assets
Cash and cash equivalents $ 4,930,123 $ 17,868,827
Accounts receivable 1,288,255 1,720,240
Prepaid expenses
and other current assets 837,238 442,469
Total current assets 7,055,616 20,031,536
Property and equipment, net 1,184,963 2,545,733
Other
'/>"/>
SOURCE Response Genetics, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related medicine news :1.
Tumors use enzyme to recruit regulatory T-cells and suppress immune response2.
Study identifies key player in the bodys immune response to chronic stress3.
Retired NYPD Lieutenants William E. Keegan, Jr., Owen McCaffery and John Moran and Tom Thees, a former COO in the financial industry, announce today the formation of H.E.A.R.T (Healing Emergency Aid Response Team) 911.4.
Response Biomedical appoints S. Wayne Kay Chief Executive Officer5.
Merck & Co., Inc. Response to Todays New York Medicaid Suit6.
Maternal depression and controlling behavior associated with increased stress response in infants7.
Family history of alcoholism affects response to drug used to treat heavy drinking8.
Molecular fingerprint of breast-cancer drug resistance can predict response to treatment9.
Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer10.
PET scans can accurately detect a breast tumors response to chemotherapy11.
DNA damage response confers a barrier for viral tumorigenesis